1980 to 2017 saw improved survival for acute myeloid leukemia

1980 to 2017 saw improved survival for acute myeloid leukemia

(HealthDay)—From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged ≥70 years, according to a study published in the June 15 issue of Cancer.

Koji Sasaki, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues identified 29,107 patients diagnosed with de novo AML between 1980 and 2017 from the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Patients were classified according to age and calendar period, and outcomes were examined within these categories.

The researchers found that for patients with AML, the overall five-year survival rates were 9, 15, 22, and 28 percent in the decades 1980 to 1989, 1990 to 1999, 2000 to 2009, and 2010 to 2017, respectively. The corresponding five-year survival rates were 24, 41, 52, and 63 percent among patients aged 15 to 39 years and 1, 2, 3, and 5 percent for those aged ≥70 years. Among adults and , four-week mortality was surprisingly high (range, 20 to 45 percent), even in . Over the calendar periods, survival continued to improve and was best in 2010 to 2017. The improvement in survival was noticeable across all , except for aged ≥70 years.

"We believe we now have many of the therapeutic tools that could improve the cure rates across all AML categories in the next decade," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.


Explore further

Patient race linked to poorer survival in acute myeloid leukemia

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Cancer

Copyright © 2021 HealthDay. All rights reserved.

Citation: 1980 to 2017 saw improved survival for acute myeloid leukemia (2021, June 10) retrieved 24 June 2021 from https://medicalxpress.com/news/2021-06-survival-acute-myeloid-leukemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments